Lentivirus is a type of retrovirus with a particle size of 80-120nm. It consists of a single-stranded RNA sequence that is transcribed into DNA and can be integrated into the host genome, resulting in persistent infection. Most lentiviral vectors are derived from HIV-1 and retain the ability to integrate into the genome of infected cells. LV is very popular in clinical applications because it can more effectively transduce non-proliferating or slowly proliferating cells. Recently, several clinical trials have used third-generation self-inactivating LV to introduce genes into hematopoietic stem cells to treat primary immunodeficiency or hemoglobinopathy. The most common application of LV is to introduce genes through chimeric antigen receptor (CAR) or cloned T cell receptor delivery to produce anti-tumor immunity.
The lentiviral vector currently used in cell therapy is derived from HIV-1, and its prototype contains nine key viral genes, namely: gag, pol, env, tat, rev, vif, vpr, vpu, nef. Among them, the gag gene can encode the core protein required by the virus; the pol gene encodes the enzyme required for viral replication; and the env gene encodes the envelope glycoprotein of the virus. These three genes encode structural proteins and proteases, which are key genes to ensure the ability of the virus to replicate and determine the targeting of the virus to infect the host. Some cis-acting elements are also required in the process of viral expression, including long terminal repeats (LTRs), TAT activation region (TAR), splicing donor and receptor sites, packaging and dimerization signals (Ψ), Rev response elements (RRE), and central and terminal polypurine regions (PPT). In theory, we need to insert the target gene we need to express with lentivirus in the middle of the LTRs at both ends, send it into the target cells and express it to achieve the expression of exogenous genes.
Using a lentiviral-mediated labeling approach, researchers investigated whether the adult hippocampus retains persistent self-renewing neural stem cells (NSCs). A single injection of a lentiviral vector expressing green fluorescent protein (LV PGK-GFP) into the subgranular zone (SGZ) of the adult hippocampus allowed for efficient, stable, and long-term labeling of self-renewing NSCs and their progeny. Interestingly, a subset of labeled cells showed the ability to proliferate multiple times and give rise to Sox2+ cells, clearly demonstrating that NSCs have the capacity to self-renew over a long period of time (up to 6 months). Furthermore, using GFP+ cells isolated from the SGZ of mice that had received LV PGK-GFP injections 3 months earlier, researchers demonstrated that some GFP+ cells exhibited basic properties of NSCs, such as self-renewal and multipotency. Lentiviral (LV)-mediated labeling studies revealed that hippocampal NSCs are not responsible for the burst of astrocyte formation, suggesting that signals released by impaired perforant pathways do not affect NSC fate decisions. Therefore, the gene delivery system using LVs is a unique approach to understand the complex nature of NSCs and may have a translational impact in gene therapy by effectively targeting NSCs.
To test whether LV PGK-GFP was successfully transduced into NSCs with long-term proliferative capacity, the researchers introduced BrdU 6 months after LV PGK-GFP injection. The hippocampus was then examined 24 hours after the last BrdU injection to identify proliferating cells. The researchers found that 6.25±1.8% of GFP+ cells in the SGZ of the DG were positive for BrdU. This observation suggests that the initially targeted cells or their progeny maintained their proliferative capacity over a 6-month period (Figure 1A). 10±1.4% of these GFP/BrdU double-labeled cells expressed the SOX2 marker (Figure 1B), which is known to represent self-renewing and multipotent NSCs. Doublecortin (DCX), a transient marker that marks neuroblasts and immature neurons, was used to measure the continuous neurogenesis of GFP+ cells. Indeed, they observed both GFP/DCX double-labeled cells (26.8±2% of GFP+ cells; n = 3 Figure 1C) and GFP/BrdU/DCX cells triple-labeled cells (60±2.3% n = 3; Figure 1D). Interestingly, these results together suggest that NSCs are continuously generated from targeted GFP+ cells and are actively generating neuroblasts even 6 months after LV injection.
Figure 1. A long-lasting NSC population in the adult hippocampus. (Suh H, et al. 2018)